288. 自己免疫性後天性凝固因子欠乏症 ［臨床試験数：189，薬物数：219（DrugBank：29），標的遺伝子数：18，標的パスウェイ数：26］
Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||ChiCTR2000035067||2020-05-11||2020-07-30||A multicentre, prospective, single arm study of bortezomib combined with glucocorticoid in the salvage treatment of relapsed / refractory acquired hemophilia A (AHA)||A multicentre, prospective, single arm study of bortezomib combined with glucocorticoid in the salvage treatment of relapsed / refractory acquired hemophilia A (AHA)||Relapsed / refractory acquired hemophilia A (AHA)||Case series:bortezomib combined with glucocorticoid;||Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College||NULL||Recruiting||Both||Case series:20;||Phase 4||China|
|October 10, 2018||4/10/2018||Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A||An Open-label Phase II Study to Determine the Efficacy and Safety of Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A||Acquired Hemophilia A||Drug: Bortezomib;Drug: Rituximab||Peking Union Medical College Hospital||NULL||Unknown status||18 Years||N/A||All||22||Phase 2||China|